How to manage difficult Crohn's disease: Optimum delivery of anti-TNFs

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 4, 2009, Pages 407-415

  Krygier, Darin S ^a   Ko, Hin Hin ^a   Bressler, Brian ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Pacific Gastroenterology Associates   (Canada)

Author keywords

Anti TNF; Crohn's disease; Immunosuppressive

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; CROHN DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; REMISSION; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 70049083606     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.25     Document Type: Review

References (49)

1. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease (8th Edition). Elsevier, MO, USA, 2459 (2008).
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121(2), 255-260 (2001).
3. Candy S, Wright J, Gerber M et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37(5), 674-678 (1995).
4. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med. 302(18), 981-987 (1980).
5. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119(4), 895-902 (2000).
6. Feagan BG, Rochon J, Fedorak RN; The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N. Engl. J. Med. 332(5), 292-297 (1995).
7. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N. Engl. J. Med. 342(22), 1627-1632 (2000).
8. Schreiber S, Nikolaus S, Hampe J et al. Tumour necrosis factor α and interleukin β in relapse of Crohn's disease. Lancet 353(9151), 459-461 (1999).
9. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008).
10. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine 7(3), 251-259 (1995).
11. Targan SR, Hanauer SB, van Deventer SJH et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor for Crohn's disease. N. Engl. J. Med. 337, 1029-1036 (1997).
12. Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I study group, maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359(9317), 1541-1549 (2002).
13. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999).
14. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004).
15. Sands BE, Blank MA, Patel K et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2(10), 912-920 (2004).
16. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 30(2), 323-333 (2006).
17. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: the CHARM trial. Gastroenterology 132, 52-65 (2007).
18. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007).
19. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Eng. J. Med. 357(3), 239-250 (2007).
20. Vermeire S, Abreu MT, D'Haens G et al. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the WELCOME study. Gastroenterology 134(4), A-67 (2008) (Abstract 494).
21. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126(6), 1593-1610 (2004).
22. Maser EA, Villela R, Silverber MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 4(10), 1248-1254 (2006).
23. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N. Eng. J. Med. 348, 601-608 (2003).
24. Regueiro M, Siemanowski B, Kip KE et al. Infliximab dose intensification in Crohn's disease. Inflamm. Bowel Dis. 13(9), 1093-1099 (2007).
25. Kaplan GG, Hur C, Korzenik J et al. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment. Pharmacol. Ther. 26(11-12), 1509-1520 (2007).
26. Robin X, Serre-Debeauvais F, Phelip JM et al. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18, 917-925 (2003).
27. Siemanowski B, Kip K, Pevy S et al. Adjustment in infliximab dose or dosing interval in Crohn's disease: experience from the University of Pittsburgh. Gastroenterology 130, A-142 (2006) (Abstract 924).
28. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2, 542-553 (2004).
29. Feagan BG, McDonald JW, Panaccione R et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology 135(1), 294-295 (2008).
30. Sandborn W, Rutgeerts, P, Reinishch W et al. Study of biologic and immunomodulator naive patients in Crohn's disease. Am. J. Gastroenterol. 103, 1117 (2008).
31. Van Assche G, Magdelaine-Beuzeline C, D'Hanes G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled inflixmab maintenance: a randomized trial. Gastroenterology 134, 1861-1868 (2008).
32. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56(9), 1232-1239 (2007).
33. West R, Zelinkova Z, Wolbink G et al. Does immunogenicity play a role in adalimumab treatment or Crohn's disease? J. Crohn's Colitis 2(1), 17 (2008) (DDW Abstract W1241).
34. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab for induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146(12), 829-838 (2007).
35. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357(3), 239-250 (2007).
36. Sandborn WJ, Colombel JF, Enns R et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N. Eng. J. Med. 353, 1912-1925 (2005).
37. Panaccione R, Colombel JF, Sandborn WJ et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease through 2 years. Gastroenterology 134(4), A-134 (2008) (Abstract 920).
38. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8, 244-250 (2002).
39. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105, 1716-1723 (1993).
40. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63, 433-442 (2006).
41. Colombel JF, Hebuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease tresred with certolizumab pegol: first result of the MUSIC clinical trial. Am. J. Gastroenterol. 103, 13 (2008).
42. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).
43. Goekoop-Ruiterman Y, De Vries-Bouwstra J, Allaart C et al. Clinical and radiographic outcome of four different treatment strategies in patient with early rheumatoid arthritis (the BeSt study); a randomized controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
44. Lemann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128, 1812-1818 (2005).
45. Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastoenterology 130, 1054-1061 (2006).
46. Costes L, Colombel JF, Mary JY et al. Long term follow-up of a cohort of steroid dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. J. Crohn's Colitis 2(1), 8 (2008) (DDW Abstract 921).
47. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660-667 (2008).
48. Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn's disease. Gastroenterology 130, 650-656 (2006).
49. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin. Gastroenterol. Hepatol. 4, 621-630 (2006).